JAK2 inhibitors like baricitinib, gandotinib and lestaurtinib are being tested in clinical trials for a variety of diseases including acute myeloid leukemia (Hexner et al., 2008; Kubo et al., 2016; Verstovsek et al., 2017). Here, JAK2 is linked to acute myeloid leukemia.